| Literature DB >> 23418502 |
Klara Lundblom1, Linda Murungi, Victoria Nyaga, Daniel Olsson, Josea Rono, Faith Osier, Edna Ogada, Scott Montgomery, J Anthony G Scott, Kevin Marsh, Anna Färnert.
Abstract
Children in malaria endemic areas acquire immunity to severe malaria faster than to mild malaria. Only a minority of children suffers from severe malaria and it is not known what determines this. The aim of this study was to establish how P. falciparum infections during the first years of life affect the risk of severe malaria. A matched case-control study was nested within a large birth cohort set up to study the immunoepidemiology of pneumococci on the Kenyan coast. Infection patterns in three-monthly blood samples in cohort children admitted to hospital with severe malaria were compared to controls matched on age, residential location and time of sampling. P. falciparum detected at least once from birth conferred an increased risk of severe malaria and particularly if multiclonal infections, as characterized by genotyping of a polymorphic antigen gene, were ever detected. The results show for the first time that children with severe malaria have more infections early in life compared to community controls. These findings provide important insights on the immunity to severe disease, knowledge essential for the development of a vaccine against severe malaria.Entities:
Mesh:
Year: 2013 PMID: 23418502 PMCID: PMC3572150 DOI: 10.1371/journal.pone.0056032
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Matched case-control study profile.
Figure 2Syndromes overlap and mortality among the 61 cohort children admitted with severe malaria to Kilifi District Hospital.
Four children died (marked *).
Characteristics of the study population.
| Characteristics | Cases (n = 61) | Controls (n = 161) |
| Sex female, n (%) | 31 (51) | 78 (48) |
| Age (months) at the time of case admissiona, mean (range) all | 19.3 (1.9–37.0) | 19.5 (1.6–37.5) |
| 42 risk setsb | 12.5 (3.9–26.9) | 12.5 (2.3–28.2) |
| Number of three-monthly visits per child, mean (range) | 2.77 (1–8) | 3.09 (1–8) |
| Proportion parasite positive visitsc, n (%) | 17/150 (11) | 30/432 (7) |
| Proportion of children with at least one parasite positive visitc, n (%) | 20/61 (33) | 25/161(15) |
| Proportion of children with at least one antibody positive visitd, n (%) | 44/61 (75) | 105/161 (70) |
| Visits with fever, n (% of visits) | 9/169 (5.3) | 27/498 (5.4) |
| Visits with fever and parasites (by microscopy), n (% of visits) | 2/169 (1.2) | 10/498 (2.0) |
a. age at case admission of the cases and respective controls.
b. restricted to the 42 risk sets where case was younger than 2 years and 3 months at the severe malaria admission and thus had complete follow up periods before admission,
c. including PCR and microscopy results.
d. antibodies to schizont extract detected in at least one of the three most recent visits before admission in the cases and corresponding time in the controls.
Risk of severe malaria associated with parasite positivity, number of clones and antibodies to schizont extract in three-monthly visits before admission.
| Exposure | OR (95% CI)b |
|
| Negative in all | 1 (ref) | – |
| Parasite positive in anyc | 3.70 (1.25–10.92) | 0.018 |
| Negative in all | 1 (ref) | – |
| At most 1 clone d | 4.30 (1.12–16.46) | 0.033 |
| ≥2 clones in any sample d | 15.32 (1.49–157.40) | 0.022 |
| Negative in all | 1 (ref) | – |
| Antibody positive in any e | 0.76 (0.31–1.89) | 0.558 |
Conditional logistic regression adjusted for log number of visits including 42 risk sets where the case was no older than 2 years and 3 months at the time of severe malaria episode and thus had samples until three months before the admissiona.
a. excluding 13 risk sets with children with longer time since their last visit (4–47 months).
b. adjusted for log number of visits in the period before the severe admission of the cases and respective periods in the controls.
c. including PCR and microscopy results.
d. including only risk sets where PCR results were available (n = 41).
e. antibodies to schizont extract detected in at least one of the three most recent visits before admission in the cases and corresponding time in the controls, including 40 risk sets where samples for antibody analysis were available.
Assessment of exposure in three-monthly visits from birth until admissiona in 61 children admitted with severe malaria.
| Impaired consciousnessb n(%) | Non-cerebral malariac n (%) | ||
| Number of children | 32 | 29 | |
| Parasite positive visits | 0 | 25 (78) | 19 (65) |
| 1 | 7 (22) | 8 (28) | |
| 2 | 0 | 2 (7) | |
| Proportion positive | 7 (22) | 10 (34) | |
| Number of clones in PCR positive visits | Only 1 cloned | 6 (19) | 5 (17) |
| Ever multiclonal | 0 | 5 (17) | |
| Cumulative numbere, median (range) | 1 (1–1) | 2 (1–6) | |
| Antibody positive visits | Proportion positive | 19/31 (62) | 25/28 (89) |
| Exposedf | 20/32 (63) | 25/29 (86) | |
| Not exposedg | 12/32 (37) | 4/29 (14) | |
a. samples until 2 years of age at most.
b. cases with impaired consciousness with or without other syndromes.
c. including respiratory distress and severe malaria anemia and not impaired consciousness.
d. ever detected in all samples.
e. total number of clones detected in an individual including all visits.
f. exposed (parasite positive and/or antibodies to schizont extract at least once) n (%).
g. not exposed as determined by PCR and antibodies to schizont extract.
Risk of impaired consciousness in relation to parasite exposure in three-monthly samples among 61 cases with severe malaria.
| Exposure | OR (95% CI) |
| |
| Ever parasite positive a | 0.50 (0.08–2.49) | 0.46 | |
| Ever multiple clones b | 0.44 (0–4.91) | 0.51 | |
| Ever antibody positive c | 0.15 (0.03–1.23) | 0.06 | |
Unmatched case-control analysis performed with exact logistic regression adjusted for age and number of samples, defining patients with impaired consciousness as “cases” (n = 32) and those with non-cerebral severe malaria as “controls” (n = 29).
a. including PCR and/or microscopy results.
b. including only PCR results.
c. antibodies to schizont extract detected in at least one of the three most recent visits before admission in the cases and corresponding time in the controls.